The gene CHEK2 is located at 22q12.1 and codes for the protein checkpoint kinase 2, a protein that functions in cell cycle regulation and is a known tumor suppressor. CHEK2 is activated due to DNA damage generating a cascade of protein phosphorylation events involving key mediators such as Cdc25A, Cdc25C, and BRCA1. The phosphorylation of these substrates leads to cell cycle arrest, DNA repair, or apoptosis. Pathogenic variants in the gene CHEK2 are known to be associated with an increased lifetime risk for developing male and female breast, colorectal, and prostate cancer. Preliminary literature suggests certain pathogenic variants in the gene CHEK2 may be associated with an increased lifetime risk for developing other cancers, such as papillary thyroid cancer. Four studies in the literature support that a pathogenic variant in the gene CHEK2 may lead to an increased lifetime risk of developing clear cell renal carcinoma. Our patient has a personal history of clear cell renal and gastric cancer, a family history of clear cell renal and breast cancer, and a IVS2+1G>A pathogenic variant in CHEK2. This case study supports the limited evidence that pathogenic variants in CHEK2 may be associated with an increased lifetime risk of developing clear cell renal carcinoma. Further investigation into this association could impact the recommended genetic testing and medical management for individuals with a personal or family history of clear cell renal cancer.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Cancer Genetics
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Current perspectives on CHEK2 mutations in breast cancer.Breast Cancer (Dove Med Press). 2017; 9: 331-335https://doi.org/10.2147/BCTT.S111394
- Prevalence of germline mutaitons in cancer susceptibility genes in patients with advanced renal cell carcinoma.JAMA Oncol. 2018; 4: 1228-1235https://doi.org/10.1001/jamaoncol.2018.1986
- CHEK2 Is a multiorgan cancer susceptibility gene.Am. J. Hum. Genet. 2004; 75: 1131-1135https://doi.org/10.1086/426403
- Risk of breast cancer among carriers of pathogenic variants in breast cancer predisposition genes varies by polygenic risk score.Journal of Clinical Oncology. 2021; 39: 2564-2573https://doi.org/10.1200/JCO.20.01992
- Rare variants in BRCA2 and CHEK2 are associated with the risk of urinary tract cancers.Nature. 2016; 6https://doi.org/10.1038/srep33542
- Checkpoint Kinase 2 (CHEK2) mutation in renal cell carcinoma: a single-center experience.J Kidney Cancer VHL. 2017; 5: 19-23https://doi.org/10.15586/jkcvhl.2018.101
Memorial Sloan Kettering Cancer Center. (2021). The PROMPT Study. https://www.mskcc.org/cancer-care/risk-assessment-screening/genetic-counseling-and-testing/clinical-trials/prompt-study
- Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients.Hum. Mutat. 2020; 41: 2128-2142https://doi.org/10.1002/humu.24110
Published online: December 22, 2021
Accepted: December 20, 2021
Received in revised form: November 12, 2021
Received: August 13, 2021
Published by Elsevier Inc.